Active, not recruitingPhase 3NCT05572515

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Studying Hinman syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Janssen Research & Development, LLC
Principal Investigator
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Intervention
Teclistamab(drug)
Enrollment
614 target
Eligibility
18 years · All sexes
Timeline
20232031

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05572515 on ClinicalTrials.gov

Other trials for Hinman syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hinman syndrome

← Back to all trials